ýҕl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • ýҕl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Apr 21 2025

Full Issue

Amid Tariff Threats, Lilly Vows To Make New Weight Loss Pill In US

Meanwhile, Stat reports that in Ireland — a global pharmaceutical hub — potential U.S. tariffs are raising concerns. Also in the news: Novo Nordisk, PBM legislation in statehouses, same-day prescription deliveries, and more.

Eli Lilly & Co. plans to manufacture its new weight-loss pill in the US for patients around the world as President Donald Trump presses companies to move production back to American shores. (Muller, 4/18)

The hulking factories are tucked away off the roads around the village of Ringaskiddy — operated by the likes of Pfizer, Johnson & Johnson, and BioMarin, whose plant featured signs last week touting a new facility “coming Q1 2027.” (Joseph, 4/21)

More on the high price of prescription drugs —

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have major ramifications for the Medicare drug price negotiation program, a signature accomplishment of former President Biden that President Trump has also embraced. (Wilkerson, 4/21)

New patients have recently begun streaming into Del-Kar Pharmacy — an independent, 65-year-old drugstore in North Lawndale — after nearby Walgreens stores closed. The new customers would be a blessing for many businesses, but for Del-Kar it means losing money on many prescriptions. The reimbursements the drugstore receives for filling orders are often less than the cost of filling them, said second-generation owner and pharmacist Edwin Muldrow. (Petrella and Schencker, 4/20)

At least half a dozen states are weighing new restrictions aimed at limiting pharmacy benefit managers' ability to influence drug prices, including prohibitions on steering business to affiliated pharmacies. With Congress gridlocked on PBM legislation, more states are taking the lead in addressing industry practices that critics say drive up costs and are pushing independent pharmacies out of business. (Reed, 4/21)

A 10-year-old girl who'll keep going to the local clinic for the medications to suppress the HIV virus — forgetting that it's now closed. A house painter who no longer has the strength to do his work. A teenager who finds comfort in religious music as she wonders why it was her fate to be born HIV positive — and how she will find the medications she needs to keep the virus at bay. (Emanuel and Davis, 4/20)

Also —

America’s two largest retailers want to deliver prescriptions to your doorstep in as little as a few hours. Amazon and Walmart are undergoing national expansions in same-day prescription deliveries. They’re joining a trend that has gained momentum since the COVID-19 pandemic, with drugstore chains and companies like Instacart and DoorDash rushing to deliver prescriptions as soon as possible. Fast prescription delivery options are growing as traditional drugstores close and more people use telemedicine or subscription-based care that encourages regular deliveries. (Murphy, 4/20)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 29
  • Thursday, May 28
  • Wednesday, May 27
  • Tuesday, May 26
  • Friday, May 22
  • Thursday, May 21
More Morning Briefings
RSS Feeds
  • ýҕl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF